NUCLIDIUM and University Hospital Basel Receive NETRF Investigator Award to Initiate Phase 1 Trial with Novel Copper-based Radiotheranostic Program TraceNETTM in Neuroendocrine Tumours
NUCLIDIUM today announced that the Neuroendocrine Tumors Research Foundation ("NETRF") has selected the company and its collaboration partner the University Hospital Basel (Universitätsspital Basel
Nuclidium Trace Leila Jaafar Division Head Radiopharmaceutical Chemistry Neuroendocrine Tumors Research Foundation Trophic Communications University Hospital Basel Universit
Source: finanznachrichten.de